These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 24198330)

  • 1. New tests for prostate cancer.
    O'Hanlon LH
    J Natl Cancer Inst; 2013 Nov; 105(22):1672-4. PubMed ID: 24198330
    [No Abstract]   [Full Text] [Related]  

  • 2. A guide to a new prostate cancer tests.
    Johns Hopkins Med Lett Health After 50; 2014 May; 29(3):4-5. PubMed ID: 25097944
    [No Abstract]   [Full Text] [Related]  

  • 3. New tests for prostate cancer may be nearing the clinic.
    Tuma RS
    J Natl Cancer Inst; 2010 Jun; 102(11):752-4. PubMed ID: 20498428
    [No Abstract]   [Full Text] [Related]  

  • 4. Molecular diagnosis of prostate cancer: PCA3 and TMPRSS2:ERG gene fusion.
    Salagierski M; Schalken JA
    J Urol; 2012 Mar; 187(3):795-801. PubMed ID: 22245323
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Study supports PSA velocity risk count.
    Fillon M
    J Natl Cancer Inst; 2012 Jul; 104(14):1042-3. PubMed ID: 22781432
    [No Abstract]   [Full Text] [Related]  

  • 6. Ki67 and BUBR1 may discriminate clinically insignificant prostate cancer in the PSA range <4 ng/ml.
    Nagao K; Yamamoto Y; Hara T; Komatsu H; Inoue R; Matsuda K; Matsumoto H; Hara T; Sakano S; Baba Y; Matsuyama H
    Jpn J Clin Oncol; 2011 Apr; 41(4):555-64. PubMed ID: 21233104
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prostate cancer detection in the "grey area" of prostate-specific antigen below 10 ng/ml: head-to-head comparison of the updated PCPT calculator and Chun's nomogram, two risk estimators incorporating prostate cancer antigen 3.
    Perdonà S; Cavadas V; Di Lorenzo G; Damiano R; Chiappetta G; Del Prete P; Franco R; Azzarito G; Scala S; Arra C; De Sio M; Autorino R
    Eur Urol; 2011 Jan; 59(1):81-7. PubMed ID: 20947244
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Contemporary role of prostate cancer antigen 3 in the management of prostate cancer.
    Auprich M; Bjartell A; Chun FK; de la Taille A; Freedland SJ; Haese A; Schalken J; Stenzl A; Tombal B; van der Poel H
    Eur Urol; 2011 Nov; 60(5):1045-54. PubMed ID: 21871709
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The dilemma of prostate-specific antigen testing.
    Leach R; Thompson IM
    Arch Intern Med; 2012 Jun; 172(11):835-6. PubMed ID: 22905350
    [No Abstract]   [Full Text] [Related]  

  • 10. Risk stratification and validation of prostate specific antigen density as independent predictor of progression in men with low risk prostate cancer during active surveillance.
    San Francisco IF; Werner L; Regan MM; Garnick MB; Bubley G; DeWolf WC
    J Urol; 2011 Feb; 185(2):471-6. PubMed ID: 21167525
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PSA kinetics: no substitute for annual biopsy in prostate cancer surveillance?
    Schmidt C
    J Natl Cancer Inst; 2010 Oct; 102(20):1533-5. PubMed ID: 20935269
    [No Abstract]   [Full Text] [Related]  

  • 12. Further support for active surveillance in the management of low-volume, low-grade prostate cancer.
    Albertsen P
    Eur Urol; 2010 Dec; 58(6):836-7. PubMed ID: 20851512
    [No Abstract]   [Full Text] [Related]  

  • 13. Contemporary role of prostate cancer gene 3 in the management of prostate cancer.
    Roobol MJ
    Curr Opin Urol; 2011 May; 21(3):225-9. PubMed ID: 21301341
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prostate cancer diagnosis among men with isolated high-grade intraepithelial neoplasia enrolled onto a 3-year prospective phase III clinical trial of oral toremifene.
    Taneja SS; Morton R; Barnette G; Sieber P; Hancock ML; Steiner M
    J Clin Oncol; 2013 Feb; 31(5):523-9. PubMed ID: 23295793
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prostate cancer antigen 3 score accurately predicts tumour volume and might help in selecting prostate cancer patients for active surveillance.
    Ploussard G; Durand X; Xylinas E; Moutereau S; Radulescu C; Forgue A; Nicolaiew N; Terry S; Allory Y; Loric S; Salomon L; Vacherot F; de la Taille A
    Eur Urol; 2011 Mar; 59(3):422-9. PubMed ID: 21156337
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PSGR and PCA3 as biomarkers for the detection of prostate cancer in urine.
    Rigau M; Morote J; Mir MC; Ballesteros C; Ortega I; Sanchez A; Colás E; Garcia M; Ruiz A; Abal M; Planas J; Reventós J; Doll A
    Prostate; 2010 Dec; 70(16):1760-7. PubMed ID: 20672322
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Low-risk prostate cancer patients without visible tumor (T1c) on multiparametric MRI could qualify for active surveillance candidate even if they did not meet inclusion criteria of active surveillance protocol.
    Lee DH; Koo KC; Lee SH; Rha KH; Choi YD; Hong SJ; Chung BH
    Jpn J Clin Oncol; 2013 May; 43(5):553-8. PubMed ID: 23580758
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prospective multi-institutional study evaluating the performance of prostate cancer risk calculators.
    Nam RK; Kattan MW; Chin JL; Trachtenberg J; Singal R; Rendon R; Klotz LH; Sugar L; Sherman C; Izawa J; Bell D; Stanimirovic A; Venkateswaran V; Diamandis EP; Yu C; Loblaw DA; Narod SA
    J Clin Oncol; 2011 Aug; 29(22):2959-64. PubMed ID: 21690464
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Assessing risk: does this patient have prostate cancer?
    Carter HB
    J Natl Cancer Inst; 2006 Apr; 98(8):506-7. PubMed ID: 16622114
    [No Abstract]   [Full Text] [Related]  

  • 20. Performance of prostate cancer antigen 3 (PCA3) and prostate-specific antigen in Prescreened men: reproducibility and detection characteristics for prostate cancer patients with high PCA3 scores (≥ 100).
    Roobol MJ; Schröder FH; van Leenders GL; Hessels D; van den Bergh RC; Wolters T; van Leeuwen PJ
    Eur Urol; 2010 Dec; 58(6):893-9. PubMed ID: 20933321
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.